Cor Vasa 2025, 67(Suppl.2):5-6 | DOI: 10.33678/cor.2025.060

(Beta-blockers in cardiovascular diseases 2025 - editorial)

Jiří Vítoveca, b
a I. interní kardioangiologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně, Brno, Česká republika
b Ústav farmakologie a toxikologie, Farmaceutická fakulta Masarykovy univerzity, Brno, Česká republika

Received: March 30, 2025; Accepted: March 30, 2025; Prepublished online: March 31, 2025; Published: April 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J. (Beta-blockers in cardiovascular diseases 2025 - editorial). Cor Vasa. 2025;67(Suppl.2):5-6. doi: 10.33678/cor.2025.060.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Waagstein F, Hjakmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036. Go to original source... Go to PubMed...
    2. Vítovec J, Kollár P, Lábr K. Betablokátory v léčbě kardiovaskulárních onemocnění. Praha: Grada Publishing, 2022:130.

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content